Cantor Fitzgerald analyst Charles Duncan views the U.S. Court of Appeals upholding a decision to invalidate four Ampyra patents as "unsurprising." He notes that he didn't ascribe value to Ampyra due to the prior court rulings, which he predicted would be upheld on appeal. While Duncan anticipates a steep decline in Ampyra sales as generics now have an opportunity to enter the market, and that this court decision may prompt generics to launch soon, he believes the news should clear an overhang on Acorda Therapeutics shares. His valuation of the company remains focused on Inbrija in Parkinson's as being the main growth driver, with "robust" sales projected in both the U.S. and European markets, "eventually." The analyst reiterates a Neutral rating on Acorda Therapeutics with a $32 price target.